Over 1 million annual testing opportunities in US
Q4 targeted for early access launch
IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has begun the manufacturing process for the distributable version of its patented transplant technology. A method of checking for signs of graft damage in transplant recipients, the assay measures levels of donor derived cell-free DNA (dd-cfDNA) in the blood. Early access for this RUO kit is expected to open in late Q4 2023.
“We believe that our patented method of assessing graft damage offers distinct benefits over competing and more invasive approaches,” said Josh Riggs, Oncocyte’s CEO. “Oncocyte is committed to being a partner for the transplant community. Our test provides a simple, easy-to-use workflow, on droplet digital PCR, so researchers can perform in-house dd-cfDNA testing. We believe opening access to our technology supports broader research than what is addressable with today’s centralized testing. We look forward to updating investors on rapid manufacturing progress as we move to commercialization.”
The test can typically be accomplished within the same day, without the necessity of donor genotyping. Results will be provided in both percentage and precise quantification of dd-cfDNA.
